Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625460 | 0.82 | FFAR4 (0.35) | FFAR4SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL19626521 | 0.78 | APP (0.40) | RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL19626603 | 0.77 | ALDH1A1 (0.46) | FFAR4SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL17625939 | 0.72 | FFAR4 (0.37) | FFAR4SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL19626765 | 0.72 | GRIA2 (0.32) | ALDH1A1 | |
| SCHEMBL19625457 | 0.70 | FFAR4 (0.41) | FFAR4SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL16250650 | 0.68 | ALDH1A1 (0.43) | FFAR4SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL19626512 | 0.67 | MAPT (0.42) | SMN1; SMN2RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL17625929 | 0.67 | FFAR4 (0.43) | FFAR4 | |
| SCHEMBL9832077 | 0.65 | RAB9A (0.46) | FFAR4SMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | FFAR4 1815/4885SMN1; SMN2 4828/4885RAB9A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.